Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Noble Corporation plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Noble Corporation plc trades at $44.21 (market cap $7.10B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.2× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NE | |
|---|---|---|
Market Cap | $29.60B | $7.10B |
Sector | Health | Technology |
52-Week High | $491.22 | $54.37 |
52-Week Low | $205.48 | $26.61 |
Enterprise Value | $27.56B | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Noble Corporation (NE) trades at $44.21, up 1.52% today, with a mixed technical and fundamental backdrop. The stock exhibits a bullish trend in moving averages but faces resistance near $45-$46. Recent Q2 2026 earnings of $0.01 per share missed expectations, though the company secured $200 million in new contracts and maintains a $6.8 billion backlog. Positive cash flow from operations of $952 million in 2025 supports financial stability, but net income declined year-over-year.
The outlook is cautiously optimistic, with a consensus price target of $46 offering modest upside. Key opportunities include strong contract backlog and operational cash flow, while risks involve earnings volatility, ongoing legal investigations, and competitive pressures in offshore drilling. Analyst sentiment is divided, with 31% buy ratings reflecting balanced optimism and caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
